Newborn screening
Advanced analysis to identify serious, actionable childhood disorders early, enabling faster diagnosis, earlier intervention, and more personalised care
What is newborn screening (NBS)?
Newborn screening (NBS) is a public health programme designed to identify newborns who may be at increased risk of certain serious genetic, metabolic, endocrine, or other congenital conditions. It is typically performed shortly after birth, before symptoms appear, allowing for early diagnosis and timely intervention.
The purpose of newborn screening is to provide early detection of severe and life-altering conditions that are not apparent at birth, but for which early treatment and management can significantly improve health outcomes and quality of life. Newborn screening can detect conditions that:
- Do not cause symptoms at birth
- Manifest shortly after birth
- Develop later in infancy or early childhood
Early identification enables healthcare providers to initiate monitoring, treatment, or preventive measures before irreversible damage occurs.
Why is newborn screening important?
Many serious genetic disorders may not be clinically apparent during the newborn period. Without screening, diagnosis often occurs only after symptoms emerge, by which time significant and sometimes irreversible damage may have already occurred. Prompt identification and management can help prevent or reduce the severity of:
- Developmental delay
- Cognitive impairment
- Physical disability
- Neurological degeneration
- Liver disease
- Blindness
- Malnutrition
- Premature death
Although treatment can begin after symptoms appear, a child’s growth and development may already have been adversely affected. Therefore, initiating treatment as early as possible offers the greatest opportunity to prevent or minimise disease-related complications and improve long-term outcomes.
Genetic newborn screening
Genetic newborn screening expands upon traditional newborn screening by using advanced genomic technologies to analyse genes associated with serious, actionable childhood disorders.
Unlike conventional newborn screening, which primarily relies on biochemical testing to detect evidence of disease, genetic newborn screening examines DNA to identify disease-causing variants before symptoms develop.
This approach enables the detection of a broader range of clinically significant disorders and can provide valuable information to support earlier diagnosis, intervention, and personalised care.
Why recommend genetic newborn screening
Genetic newborn screening is designed to complement, rather than replace, existing national newborn screening programmes.
Expands disease detection: Each country has its own newborn screening programme and tests for a different number of conditions, depending on local regulations, healthcare priorities, and available resources. As a result, some treatable genetic conditions may not be included in standard screening panels.
Genetic newborn screening can screen for additional disorders beyond those covered by national programmes, helping to identify children who may otherwise remain undiagnosed until symptoms appear.
Uses advanced genomic technology: Genetic newborn screening utilises advanced technologies such as:
- Next-generation sequencing (NGS)
- Multiplex ligation-dependent probe amplification (MLPA)
These technologies enable highly accurate detection of disease-causing genetic variants and provide information that complements conventional biochemical testing methods.
Expandable and future-ready: Genetic screening panels can be readily expanded to include additional clinically significant and highly penetrant genes as scientific evidence and treatment options continue to evolve.
This flexibility allows screening programmes to adapt to advances in genomic medicine and emerging therapeutic opportunities.
Supports earlier intervention: By identifying at-risk children before symptoms develop, genetic newborn screening can provide opportunities for:
- Earlier diagnosis
- Earlier clinical monitoring
- Timely treatment initiation
- Improved disease management
- Better long-term health outcomes
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?
Certified laboratories
